Although HMTs are reported to be correlated with the progression of breast cancer while HMT inhibitors targeting PRMT3, PRMT4, PRMT5, and PRMT6 have been reported to display tumor inhibition preclinically, few drugs can progress to the clinical stage (Wang S.M. et al., 2019). Here, PRMT5 is linked to breast carcinoma.